Pleiotropic effects of niacin: Current possibilities for its clinical use
Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease. Niacin favorably influences all lipoprotein classes, including lipoprotein[a],and belongs to the most potent hypolipidemic drugs for increasing HDL-...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2016-12-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/acph-2016-0043 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572504621711360 |
|---|---|
| author | Zeman Miroslav Vecka Marek Perlík František Staňková Barbora Hromádka Robert Tvrzická Eva Širc Jakub Hrib Jakub Žák Aleš |
| author_facet | Zeman Miroslav Vecka Marek Perlík František Staňková Barbora Hromádka Robert Tvrzická Eva Širc Jakub Hrib Jakub Žák Aleš |
| author_sort | Zeman Miroslav |
| collection | DOAJ |
| description | Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease. Niacin favorably influences all lipoprotein classes, including lipoprotein[a],and belongs to the most potent hypolipidemic drugs for increasing HDL-C. Moreover, niacin causes favorable changes to the qualitative composition of lipoprotein HDL. In addition to its pronounced hypolipidemic action, niacin exerts many other, non-hypolipidemic effects (e.g., antioxidative, anti-inflammatory, antithrombotic), which favorably influence the development and progression of atherosclerosis. These effects are dependent on activation of the specific receptor HCA2. Recent results published by the two large clinical studies, AIM-HIGH and HPS2-THRIVE, have led to the impugnation of niacin’s role in future clinical practice. However, due to several methodological flaws in the AIM-HIGH and HPS2-THRIVE studies, the pleiotropic effects of niacin now deserve thorough evaluation. This review summarizes the present and possible future use of niacin in clinical practice in light of its newly recognized pleiotropic effects. |
| format | Article |
| id | doaj-art-b9b87299d0d64ab6961ef47c8cf12f0f |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2016-12-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-b9b87299d0d64ab6961ef47c8cf12f0f2025-02-02T09:57:54ZengSciendoActa Pharmaceutica1846-95582016-12-0166444946910.1515/acph-2016-0043acph-2016-0043Pleiotropic effects of niacin: Current possibilities for its clinical useZeman Miroslav0Vecka Marek1Perlík František2Staňková Barbora3Hromádka Robert4Tvrzická Eva5Širc Jakub6Hrib Jakub7Žák Aleš84th Department of Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czechia4th Department of Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, CzechiaInstitute of Pharmacology, 1st Faculty of MedicineCharles University in Prague, Prague, Czechia4th Department of Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, CzechiaResearch and Development Center, C2P s.r.o., Chlumec/n Cidlinou, Czechia4th Department of Medicine, 1st Faculty of Medicine, Charles University in PraguePrague, CzechiaInstitute of Macromolecular, Chemistry, Academy of Sciences of the Czech Republic Prague, CzechiaInstitute of Macromolecular, Chemistry, Academy of Sciences of the Czech Republic Prague, Czechia4th Department of Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, CzechiaNiacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease. Niacin favorably influences all lipoprotein classes, including lipoprotein[a],and belongs to the most potent hypolipidemic drugs for increasing HDL-C. Moreover, niacin causes favorable changes to the qualitative composition of lipoprotein HDL. In addition to its pronounced hypolipidemic action, niacin exerts many other, non-hypolipidemic effects (e.g., antioxidative, anti-inflammatory, antithrombotic), which favorably influence the development and progression of atherosclerosis. These effects are dependent on activation of the specific receptor HCA2. Recent results published by the two large clinical studies, AIM-HIGH and HPS2-THRIVE, have led to the impugnation of niacin’s role in future clinical practice. However, due to several methodological flaws in the AIM-HIGH and HPS2-THRIVE studies, the pleiotropic effects of niacin now deserve thorough evaluation. This review summarizes the present and possible future use of niacin in clinical practice in light of its newly recognized pleiotropic effects.https://doi.org/10.1515/acph-2016-0043niacinpleiotropic effectshca2 receptordyslipidemiacardiovascular mortality/morbidity |
| spellingShingle | Zeman Miroslav Vecka Marek Perlík František Staňková Barbora Hromádka Robert Tvrzická Eva Širc Jakub Hrib Jakub Žák Aleš Pleiotropic effects of niacin: Current possibilities for its clinical use Acta Pharmaceutica niacin pleiotropic effects hca2 receptor dyslipidemia cardiovascular mortality/morbidity |
| title | Pleiotropic effects of niacin: Current possibilities for its clinical use |
| title_full | Pleiotropic effects of niacin: Current possibilities for its clinical use |
| title_fullStr | Pleiotropic effects of niacin: Current possibilities for its clinical use |
| title_full_unstemmed | Pleiotropic effects of niacin: Current possibilities for its clinical use |
| title_short | Pleiotropic effects of niacin: Current possibilities for its clinical use |
| title_sort | pleiotropic effects of niacin current possibilities for its clinical use |
| topic | niacin pleiotropic effects hca2 receptor dyslipidemia cardiovascular mortality/morbidity |
| url | https://doi.org/10.1515/acph-2016-0043 |
| work_keys_str_mv | AT zemanmiroslav pleiotropiceffectsofniacincurrentpossibilitiesforitsclinicaluse AT veckamarek pleiotropiceffectsofniacincurrentpossibilitiesforitsclinicaluse AT perlikfrantisek pleiotropiceffectsofniacincurrentpossibilitiesforitsclinicaluse AT stankovabarbora pleiotropiceffectsofniacincurrentpossibilitiesforitsclinicaluse AT hromadkarobert pleiotropiceffectsofniacincurrentpossibilitiesforitsclinicaluse AT tvrzickaeva pleiotropiceffectsofniacincurrentpossibilitiesforitsclinicaluse AT sircjakub pleiotropiceffectsofniacincurrentpossibilitiesforitsclinicaluse AT hribjakub pleiotropiceffectsofniacincurrentpossibilitiesforitsclinicaluse AT zakales pleiotropiceffectsofniacincurrentpossibilitiesforitsclinicaluse |